Mohamed El-Far1, David B Hanna2, Madeleine Durand1,3, Etienne Larouche-Anctil1, Mohamed Sylla1, Carl Chartrand-Lefebvre1,4, Guy Cloutier1,5, Jean Philippe Goulet6, Seble Kassaye7, Roksana Karim8, Jorge R Kizer9, Audrey L French10, Stephen J Gange11, Jason M Lazar12, Howard N Hodis13, Jean-Pierre Routy14, Petronela Ancuta1,3, Nicolas Chomont1,3, Alan L Landay15, Robert C Kaplan2,16, Cécile L Tremblay1,2. 1. CHUM-Research Centre, Montréal, Quebec, Canada. 2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY. 3. Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, Quebec, Canada. 4. Département de Radiologie, Radio-oncologie et Médecine Nucléaire, Faculté de Médecine, Université de Montréal, Montréal, Quebec, Canada. 5. Département de radiologie et Institut de génie biomedical, Université de Montréal, Montréal, Quebec, Canada. 6. Caprion, Montréal, Quebec, Canada. 7. Department of Medicine, Georgetown University, Washington, DC. 8. Department of Preventive Medicine, University of Southern California, Los Angeles, CA. 9. Cardiology Section, San Francisco Veterans Affairs Health Care System, and Departments of Medicine, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA. 10. Division of Infectious Diseases, Stroger Hospital of Cook County, Chicago IL. 11. Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD. 12. Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY. 13. Atherosclerosis Research Unit, University of Southern California, Los Angeles, CA. 14. Research Institute of McGill University Health Centre, Montréal, Quebec, Canada. 15. Department of Internal Medicine, Rush University Medical Center, Chicago, IL; and. 16. Divsion of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
Abstract
BACKGROUND: Persistent inflammation in HIV infection is associated with elevated cardiovascular disease (CVD) risk, even with viral suppression. Identification of novel surrogate biomarkers can enhance CVD risk stratification and suggest novel therapies. We investigated the potential of interleukin 32 (IL-32), a proinflammatory multi-isoform cytokine, as a biomarker for subclinical carotid artery atherosclerosis in virologically suppressed women living with HIV (WLWH). METHODS AND RESULTS: Nested within the Women's Interagency HIV Study, we conducted a cross-sectional comparison of IL-32 between 399 WLWH and 100 women without HIV, followed by a case-control study of 72 WLWH (36 carotid artery plaque cases vs. 36 age-matched controls without plaque). Plasma IL-32 protein was measured by ELISA, and mRNA of IL-32 isoforms (IL-32α, β, γ, D, ε, and θ) was quantified by reverse transcription polymerase chain reaction from peripheral blood mononuclear cells. Plasma IL-32 protein levels were higher in WLWH compared with women without HIV (P = 0.02). Among WLWH, although plasma IL-32 levels did not differ significantly between plaque cases and controls, expression of IL-32 isoforms α, β, and ε mRNA was significantly higher in peripheral blood mononuclear cells from cases (P = 0.01, P = 0.005, and P = 0.018, respectively). Upregulation of IL-32β and IL-32ε among WLWH with carotid artery plaque persisted after adjustment for age, race/ethnicity, smoking, systolic blood pressure, body mass index, and history of hepatitis C virus (P = 0.04 and P = 0.045); the adjusted association for IL-32α was marginally significant (P = 0.07). CONCLUSIONS: IL-32 isoforms should be studied further as potential CVD biomarkers. This is of particular interest in WLWH by virtue of altered IL-32 levels in this population.
BACKGROUND: Persistent inflammation in HIV infection is associated with elevated cardiovascular disease (CVD) risk, even with viral suppression. Identification of novel surrogate biomarkers can enhance CVD risk stratification and suggest novel therapies. We investigated the potential of interleukin 32 (IL-32), a proinflammatory multi-isoform cytokine, as a biomarker for subclinical carotid artery atherosclerosis in virologically suppressed women living with HIV (WLWH). METHODS AND RESULTS: Nested within the Women's Interagency HIV Study, we conducted a cross-sectional comparison of IL-32 between 399 WLWH and 100 women without HIV, followed by a case-control study of 72 WLWH (36 carotid artery plaque cases vs. 36 age-matched controls without plaque). Plasma IL-32 protein was measured by ELISA, and mRNA of IL-32 isoforms (IL-32α, β, γ, D, ε, and θ) was quantified by reverse transcription polymerase chain reaction from peripheral blood mononuclear cells. Plasma IL-32 protein levels were higher in WLWH compared with women without HIV (P = 0.02). Among WLWH, although plasma IL-32 levels did not differ significantly between plaque cases and controls, expression of IL-32 isoforms α, β, and ε mRNA was significantly higher in peripheral blood mononuclear cells from cases (P = 0.01, P = 0.005, and P = 0.018, respectively). Upregulation of IL-32β and IL-32ε among WLWH with carotid artery plaque persisted after adjustment for age, race/ethnicity, smoking, systolic blood pressure, body mass index, and history of hepatitis C virus (P = 0.04 and P = 0.045); the adjusted association for IL-32α was marginally significant (P = 0.07). CONCLUSIONS: IL-32 isoforms should be studied further as potential CVD biomarkers. This is of particular interest in WLWH by virtue of altered IL-32 levels in this population.
Authors: David B Hanna; Wendy S Post; Jennifer A Deal; Howard N Hodis; Lisa P Jacobson; Wendy J Mack; Kathryn Anastos; Stephen J Gange; Alan L Landay; Jason M Lazar; Frank J Palella; Phyllis C Tien; Mallory D Witt; Xiaonan Xue; Mary A Young; Robert C Kaplan; Lawrence A Kingsley Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: David M Naeger; Jeffrey N Martin; Elizabeth Sinclair; Peter W Hunt; David R Bangsberg; Frederick Hecht; Priscilla Hsue; Joseph M McCune; Steven G Deeks Journal: PLoS One Date: 2010-01-29 Impact factor: 3.240
Authors: Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly Journal: Nat Med Date: 2009-06-21 Impact factor: 53.440
Authors: Adaora A Adimora; Catalina Ramirez; Lorie Benning; Ruth M Greenblatt; Mirjam-Colette Kempf; Phyllis C Tien; Seble G Kassaye; Kathryn Anastos; Mardge Cohen; Howard Minkoff; Gina Wingood; Igho Ofotokun; Margaret A Fischl; Stephen Gange Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196
Authors: Caitlin A Moran; Anandi N Sheth; C Christina Mehta; David B Hanna; Deborah R Gustafson; Michael W Plankey; Wendy J Mack; Phyllis C Tien; Audrey L French; Elizabeth T Golub; Arshed Quyyumi; Robert C Kaplan; Ighovwerha Ofotokun Journal: AIDS Date: 2018-05-15 Impact factor: 4.632
Authors: Ece A Mutlu; Ali Keshavarzian; John Losurdo; Garth Swanson; Basile Siewe; Christopher Forsyth; Audrey French; Patricia Demarais; Yan Sun; Lars Koenig; Stephen Cox; Phillip Engen; Prachi Chakradeo; Rawan Abbasi; Annika Gorenz; Charles Burns; Alan Landay Journal: PLoS Pathog Date: 2014-02-20 Impact factor: 6.823